[Neurasthenia as a variant of the asthenic syndrome: a pharmacotherapeutic analysis modelled on tanakan therapy].
25 patients with neurasthenia were examined during 2 months of ambulatory therapy with tanakan. Taking into consideration the data of cluster analysis of symptomatology before the therapy, 2 groups of patients were selected: with hyposthenic (15 patients) and hypersthenic (10 patients) variations of the disease. The main symptom complex in both groups was an asthenic one, but symptomatology in group 1 tended to hyporeactivity and depressive range of affective spectrum, while in group 2--to hyperreactivity, hyperesthesia, irritation, anxious range of disorders. Pronounced improvement was observed in 18 cases, moderate effect--in 4 patients; in 3 cases the treatment was discontinued because of side-effects (headache, allergic reactions, etc). In group 1 efficiency of the treatment was higher and stable positive dynamics of the state was found, while in group 2 there was uneven reduction of the symptoms with partial temporary change (the exacerbation of anxious symptoms). The data obtained support correctness of the division of neurasthenia into hyposthenic and hypersthenic variations and expediency of taking into consideration such differences in therapeutic policy.